Q2 Earnings Forecast for McKesson Issued By Leerink Partnrs

Key Points

• Leerink Partners revised their Q2 2026 earnings per share (EPS) estimate for McKesson to $8.65, up from a previous forecast of $8.32.
• McKesson has recently increased its quarterly dividend to $0.82 per share from $0.71, representing a 0.4% yield.
• Multiple analysts have raised their price targets for McKesson, with Bank of America and UBS both recommending a "buy" rating, and the average target now sitting at $826.91.

McKesson Corporation (NYSE:MCK - Free Report) - Equities research analysts at Leerink Partnrs increased their Q2 2026 earnings per share (EPS) estimates for shares of McKesson in a research note issued to investors on Tuesday, September 23rd. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings per share of $8.65 for the quarter, up from their prior forecast of $8.32. The consensus estimate for McKesson's current full-year earnings is $32.77 per share.

McKesson (NYSE:MCK - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $8.26 earnings per share for the quarter, missing analysts' consensus estimates of $8.33 by ($0.07). McKesson had a negative return on equity of 196.66% and a net margin of 0.84%.The firm had revenue of $97.83 billion for the quarter, compared to analysts' expectations of $95.93 billion. During the same quarter in the previous year, the company posted $7.88 earnings per share. The firm's quarterly revenue was up 23.4% on a year-over-year basis.

Other equities analysts have also issued research reports about the company. Leerink Partners increased their target price on McKesson from $785.00 to $850.00 and gave the company an "outperform" rating in a report on Wednesday. Morgan Stanley increased their price objective on McKesson from $810.00 to $857.00 and gave the company an "overweight" rating in a report on Wednesday. Wells Fargo & Company increased their price target on shares of McKesson from $772.00 to $816.00 and gave the company an "equal weight" rating in a research note on Wednesday. Bank of America lifted their price target on shares of McKesson from $800.00 to $850.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, UBS Group upped their target price on McKesson from $820.00 to $860.00 and gave the company a "buy" rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $826.91.

McKesson Trading Down 3.0%

Shares of MCK opened at $737.65 on Friday. The firm has a market capitalization of $91.75 billion, a price-to-earnings ratio of 29.41, a PEG ratio of 1.47 and a beta of 0.51. The firm's fifty day simple moving average is $696.77 and its 200-day simple moving average is $698.45. McKesson has a twelve month low of $472.50 and a twelve month high of $770.00.

Hedge Funds Weigh In On McKesson

Hedge funds have recently bought and sold shares of the stock. Solstein Capital LLC lifted its position in shares of McKesson by 171.4% in the second quarter. Solstein Capital LLC now owns 38 shares of the company's stock valued at $28,000 after acquiring an additional 24 shares in the last quarter. Bank of Jackson Hole Trust raised its stake in McKesson by 64.3% in the 1st quarter. Bank of Jackson Hole Trust now owns 46 shares of the company's stock valued at $29,000 after purchasing an additional 18 shares during the last quarter. State of Wyoming purchased a new stake in shares of McKesson during the second quarter worth about $29,000. CBIZ Investment Advisory Services LLC raised its position in shares of McKesson by 1,366.7% in the first quarter. CBIZ Investment Advisory Services LLC now owns 44 shares of the company's stock valued at $30,000 after buying an additional 41 shares during the last quarter. Finally, GFG Capital LLC purchased a new position in shares of McKesson during the second quarter valued at approximately $30,000. Hedge funds and other institutional investors own 85.07% of the company's stock.

Insider Buying and Selling at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the business's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $663.67, for a total transaction of $218,347.43. Following the sale, the chief accounting officer directly owned 657 shares in the company, valued at approximately $436,031.19. The trade was a 33.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Brian S. Tyler sold 19,371 shares of the business's stock in a transaction that occurred on Friday, July 11th. The stock was sold at an average price of $708.09, for a total value of $13,716,411.39. Following the sale, the chief executive officer directly owned 27,872 shares in the company, valued at $19,735,884.48. This trade represents a 41.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold 43,560 shares of company stock valued at $30,438,602 in the last quarter. 0.08% of the stock is currently owned by company insiders.

McKesson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 1st. Investors of record on Tuesday, September 2nd will be issued a dividend of $0.82 per share. This is a boost from McKesson's previous quarterly dividend of $0.71. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Tuesday, September 2nd. McKesson's dividend payout ratio is currently 13.08%.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.